A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
This Phase II, multicenter, double-blind, randomized, active-controlled trial is designed to
evaluate the efficacy and safety of rhuMAb VEGF (Avastin) when administered at a dose of 5
mg/kg every 2 weeks in combination with 5 FU (fluorouracil)/leucovorin versus 5 FU/leucovorin
alone in subjects with previously untreated metastatic colorectal cancer who are not optimal
candidates to receive first-line CPT-11 (irinotecan). A total of 48 doses of rhuMAb VEGF may
be administered during this study (maximum of 96 weeks of therapy).